Harrow (HROW) Cash from Financing Activities (2011 - 2026)
Harrow (HROW) recorded quarterly Cash from Financing Activities of $48.9 million in Q1 2026, up 1069.71% quarter-over-quarter from -$5.0 million in Q4 2025, and up 212560.87% on a YoY basis from N/an in Q1 2025.
Harrow (HROW) Cash from Financing Activities (2011 - 2026) Analysis & Trends
Harrow's Cash from Financing Activities history runs 16 years deep, the most recent figure standing at $48.9 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 212560.87% year-over-year to $48.9 million; the TTM figure through Mar 2026 stood at $36.2 million (up 23.18% YoY), while the FY2025 annual figure was -$12.7 million, down 144.6% from the prior year.
- Cash from Financing Activities was $48.9 million for Q1 2026 at Harrow, up from -$5.0 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $64.2 million in Q3 2023 to a low of -$12.7 million in Q2 2025.
- Historically, Cash from Financing Activities has averaged $15.3 million across 5 years, with a median of $48000.0 in 2024.
- The sharpest annual moves came in 2022 and 2025: Cash from Financing Activities soared 2751500.0% in 2022, then sank 17452.05% in 2025.
- A 5-year view of Cash from Financing Activities shows it stood at $55.0 million in 2022, then plunged by 100.03% to -$18000.0 in 2023, then soared by 166683.33% to $30.0 million in 2024, then slumped by 116.82% to -$5.0 million in 2025, then soared by 1069.71% to $48.9 million in 2026.
- The last three Cash from Financing Activities figures came in at $48.9 million (Q1 2026), -$5.0 million (Q4 2025), and $5.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 13.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | -840.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | -1.48 Bn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | -86.10 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | -65.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 1.47 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -77.88 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | -11.62 Mn |
| 10 | Harrow | 1.25 Bn | 1.15 Bn | 27.05 Mn | 48.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 48.91 Mn |
| Mar 31, 2026 | 48.91 Mn |
| Dec 31, 2025 | -5.04 Mn |
| Dec 31, 2025 | -5.04 Mn |
| Sep 30, 2025 | 4.96 Mn |
| Sep 30, 2025 | 4.96 Mn |
| Jun 30, 2025 | -12.67 Mn |
| Jun 30, 2025 | -12.67 Mn |
| Mar 31, 2025 | 23,000.00 |
| Mar 31, 2025 | 23,000.00 |
| Dec 31, 2024 | 29.99 Mn |
| Dec 31, 2024 | 29.99 Mn |
| Sep 30, 2024 | -721,000.00 |
| Sep 30, 2024 | -721,000.00 |
| Jun 30, 2024 | 73,000.00 |
| Jun 30, 2024 | 73,000.00 |
| Mar 31, 2024 | -809,000.00 |
| Mar 31, 2024 | -809,000.00 |
| Dec 31, 2023 | -18,000.00 |
| Dec 31, 2023 | -18,000.00 |